Home > Riviste > Minerva Cardiology and Angiology > Fascicoli precedenti > Minerva Cardioangiologica 2020 June;68(3) > Minerva Cardioangiologica 2020 June;68(3):188-96



Opzioni di pubblicazione
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo



Minerva Cardioangiologica 2020 June;68(3):188-96

DOI: 10.23736/S0026-4725.20.05078-1


lingua: Inglese

Glifozines and cardiorenal outcomes

Luca DI LULLO 1 , Antonio BELLASI 2, Edoardo GUASTAMACCHIA 3, Vincenzo TRIGGIANI 3, Claudio RONCO 4, Carlo LAVALLE 5, Biagio R. DI IORIO 6, Domenico RUSSO 7, Giuseppe CIANCIOLO 8, Gaetano LA MANNA 8, Silvio SETTEMBRINI 9

1 Department of Nephrology and Dialysis, L. Parodi-Delfino Hospital, Colleferro, Rome, Italy; 2 Department of Research, Innovation, Brand Reputation, Bergamo Hospital, ASST Papa Giovanni XXIII, Bergamo, Italy; 3 Interdisciplinar Department of Medicine, University of Bari, Bari, Italy; 4 International Renal Research Institute, S. Bortolo Hospital, Vicenza, Italy; 5 Department of Cardiovascular Disease, Umberto I Polyclinic Hospital, Rome, Italy; 6 Department of Nephrology and Dialysis, “Antonio Cardarelli” Hospital, Naples, Italy; 7 Department of Public Health, University of Naples Federico II, Naples, Italy; 8 Unit of Nephrology, Dialysis and Transplantation, Department of Experimental Diagnostic and Specialty Medicine, S. Orsola Malpighi Hospital, University of Bologna, Bologna, Italy; 9 Department of Diabetology and Metabolic Disease, Pellegrini Hospital, Naples, Italy

Diabetes mellitus, with its complications, is one of the major health problems in economically developed countries and its prevalence is constantly increasing. Kidneys and heart involvement represent main comorbidities in diabetic patients often leading to organ failure. The treatments available until a few years ago are often associated with hypoglycemia, weight gain, gastro-intestinal disorders and other side effects together with serious adverse effects on renal function. The new frontiers of diabetic cardionephropathy treatment are mainly focused on delay of heart and renal failure both on diabetic and nondiabetic patients ad it was shown by last data reports. In the following review, we will focus on Gliflozins, one of the newest classes of hypoglycemic drugs that have shown to hold peculiar pharmacological properties in managing cardiac and renal complications.

KEY WORDS: Diabetes; Heart failure; Renal insufficiency, chronic

inizio pagina